Vectibix (panitumumab) / Amgen, Takeda, Dr. Reddy’s - LARVOL DELTA

FOLFOX Plus Bevacizumab Rechallenge Versus Regorafenib as Third-Line Treatment in Metastatic Colorectal Cancer: The Role of the Oxaliplatin-Free Interval. (PubMed, Cancers (Basel)) - "All patients had received first-line FOLFOX plus cetuximab or panitumumab, followed by FOLFIRI plus bevacizumab after progression...OFI was associated with PFS in a nonlinear manner, but there was no robust evidence that it modified the relative treatment effect across its continuous range. Exploratory subgroup findings based on a 6-month cutoff require external validation."

Journal • Colorectal Adenocarcinoma • Colorectal Cancer • Oncology • Solid Tumor • BRAF • KRAS

Systemic inflammation and prognosis in patients with RAS/BRAF wild-type metastatic colorectal cancer receiving anti-EGFR therapy: A real-world cohort study. (PubMed, Colorectal Dis) - "Routinely assessed markers of systemic inflammation are independently prognostic in patients with mCRC receiving anti-EGFR therapy and may serve as useful adjuncts in informing discussions with patients about prognosis."

Biomarker • Journal • Real-world evidence • Retrospective data • Colorectal Cancer • Oncology • Solid Tumor • BRAF • EREG

Population-Based Multicenter Real-World Outcomes of Encorafenib Plus Panitumumab in BRAF V600E-Mutated Metastatic Colorectal Cancer. (PubMed, Clin Colorectal Cancer) - "Encorafenib and panitumumab can be effectively combined to treat stage IV mCRC in patients with BRAF V600E mutation. Real-world outcomes indicate that the combination is tolerated with meaningful clinical efficacy."

Journal • Real-world evidence • Colorectal Cancer • Oncology • Solid Tumor • BRAF

Prognostic and predictive value of baseline derived neutrophil-to-lymphocyte ratio (dNLR) in RAS wild-type (WT) metastatic colorectal cancer (mCRC) receiving 5-fluorouracil and folinic acid (FU/FA) ± panitumumab (Pmab) maintenance: A post-hoc analysis of the PANAMA (AIO KRK 0212) trial. (ESMO 2026) - No abstract available

Clinical • Metastases • Retrospective data • Colorectal Cancer • Oncology • Solid Tumor • RAS

COLOSOTO trial: Sotorasib plus panitumumab and 5-fluorouracil in first-line treatment of frail patients with unresectable KRAS G12C mutated colorectal cancer (ESMO 2026) - No abstract available

Clinical • Colorectal Cancer • Oncology • Solid Tumor • KRAS

Depth of response and curative-intent metastasectomy in initially unresectable RAS/BRAF wild-type metastatic colorectal cancer treated with first-line panitumumab-based chemotherapy (ESMO 2026) - No abstract available

Clinical • Metastases • Colorectal Cancer • Oncology • Solid Tumor • BRAF

Panitumumab in Patients with Advanced Unresectable Colorectal Cancer Undergoing Secondary Resection in Taiwan: The PARIS Trial (ESMO 2026) - No abstract available

Clinical • Metastases • Colorectal Cancer • Oncology • Solid Tumor

Efficacy of panitumumab monotherapy in patients with advanced or metastatic RAS/RAF wild-type (wt) tumors: Results from the Drug Rediscovery Protocol (DRUP) (ESMO 2026) - No abstract available

Clinical • Metastases • Monotherapy • Oncology

FOLFOXIRI Plus Panitumumab for Left-sided RAS-wild-type Metastatic Colorectal Cancer. (PubMed, Oncologist) - "In this small US multicenter study, utilizing FOLFOXIRI with an anti-EGFR antibody for appropriately selected patients, we note among the highest response rate and PFS reported for stage IV colon cancer."

Clinical • Journal • Colon Cancer • Colorectal Cancer • Gastrointestinal Cancer • Hematological Disorders • Neutropenia • Oncology • Solid Tumor • RAS

Hiccups: An Unusual Presentation of Colon Cancer in a Young Adult (ACG 2026) - "He was staged as AJCC Stage IVC and initiated on palliative FOLFOX with subsequent addition of panitumumab...In young patients with unexplained low-SAAG ascites and evolving gastrointestinal symptoms, intractable hiccups may herald advanced peritoneal carcinomatosis. As EOCRC incidence rises, a low threshold for malignancy should be maintained when the clinical picture remains discordant with the presumed diagnosis."

Clinical • Addiction (Opioid and Alcohol) • Colon Cancer • Colorectal Cancer • Fibrosis • Hepatology • Immunology • Oncology • Peritoneal Cancer • Portal Hypertension • Solid Tumor • CDX2

Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial (clinicaltrials.gov) - P3 | N=408 | Recruiting | Sponsor: ECOG-ACRIN Cancer Research Group | Trial completion date: Jun 2034 ➔ Jun 2029

Trial completion date • Colorectal Cancer • Oncology • Solid Tumor

First-Line Systemic Treatment for Initially Unresectable Colorectal Liver Metastases: Post Hoc Analysis of the CAIRO5 Randomized Clinical Trial. (PubMed, JAMA Oncol) - P3 | "In patients with colorectal cancer and unresectable liver-only metastases (CRLM), treatment with folinic acid, fluorouracil, and oxaliplatin (FOLFOX) plus irinotecan (FOLFOXIRI) and bevacizumab vs FOLFOX/folinic acid, fluorouracil, and irinotecan (FOLFIRI) plus bevacizumab increased progression-free survival, response, and R0/R1 resection/ablation rates, as well as toxic effects in RAS/BRAFV600E-variant and/or right-sided tumors...To present long-term outcomes of treatment with FOLFOXIRI plus bevacizumab vs FOLFOX/FOLFIRI plus bevacizumab and FOLFOX/FOLFIRI plus panitumumab vs FOLFOX/FOLFIRI + bevacizumab...ACT might be considered for these patients. ClinicalTrials.gov NCT02162563."

Clinical • Journal • Retrospective data • Colorectal Cancer • Oncology • Solid Tumor

Overall Survival Analysis of the Phase III CodeBreaK 300 Study of Sotorasib Plus Panitumumab Versus Investigator's Choice in Chemorefractory KRAS G12C Colorectal Cancer. (PubMed, J Clin Oncol) - "In the phase III CodeBreaK 300 study, sotorasib 960 mg-panitumumab significantly prolonged progression-free survival (PFS) versus investigator's choice (trifluridine/tipiracil or regorafenib) in patients with KRAS G12C-mutated chemorefractory metastatic colorectal cancer (mCRC). No new safety signals were observed. Although not statistically significant, the observed OS HR and ORR along with prior PFS and safety findings support sotorasib 960 mg-panitumumab as a standard of care in patients with chemorefractory KRAS G12C mCRC."

Journal • P3 data • Colorectal Cancer • Oncology • Solid Tumor • KRAS

Liquid biopsy-guided selection for anti-EGFR re-treatment in RAS/BRAF wild-type (wt) chemorefractory metastatic colorectal cancer patients (mCRC pts): Results from the phase II randomized PARERE trial (ESMO-GI 2025) - P2 | "Background: PARERE (NCT04787341) is an open-label, multicenter, randomized phase II trial investigating the optimal sequencing of panitumumab (pani) and regorafenib (rego) in the chemorefractory setting of RAS and BRAF wt mCRC pts, who previously derived benefit from first-line anti-EGFR-containing regimens, and then received at least one line of anti-EGFR-free treatment. Pts were screened with the OncomineTM Colon cfDNA assay and those with no RAS or BRAF V600E mutations in their circulating tumor DNA (ctDNA) were randomized to receive pani followed by rego after progression (arm A) versus the reverse sequence (arm B). ctDNA-guided selection and hyperselection allows to identify RAS and BRAF wt mCRC pts who derive benefit from anti-EGFR re-treatment versus rego in the chemorefractory setting."

Biopsy • Clinical • Liquid biopsy • Metastases • P2 data • Colorectal Cancer • Oncology • Solid Tumor • BRAF • RAS • TNFRSF10C

Health-related quality of life (HRQoL) in patients with metastatic colorectal cancer (mCRC) treated with sotorasib and panitumumab (pmab) versus trifluridine/tipiracil (T/T) or regorafenib (rego) in CodeBreaK 300. (ASCO-GI 2024) - P3 | "In CodeBreaK 300, both doses of sotorasib resulted in better HRQoL and a trend to decreased risk of deterioration vs the control group. In addition to improved clinical outcomes, these findings provide further evidence on the benefit of soto+pmab in patients with chemorefractory mCRC. Clinical trial information: NCT05198934."

Clinical • HEOR • Metastases • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • KRAS

Sotorasib plus panitumumab versus standard-of-care for chemorefractory KRAS G12C-mutated metastatic colorectal cancer (mCRC): CodeBreak 300 phase III study (ESMO 2023) - P3 | "Methods In the CodeBreaK 300 (NCT05198934) global, open label study, 160 pts with chemorefractory KRAS G12C-mutated mCRC were randomized 1:1:1 to soto 960 mg daily plus pani 6 mg/kg IV (soto960+pani; n=53), soto 240 mg daily plus pani 6 mg/kg IV (soto240+pani, n=53), or investigator's choice of TAS-102 or regorafenib (n=54). Table: LBA10 Efficacy by BICR Soto960+Pani n=53 Soto240+Pani n=53 SOC n=54 Median PFS, months (95% CI) 5.6 (4.21, 6.31) 3.9 (3.71, 5.75) 2.2 (1.94, 3.91) ORR, % (95% CI) 26.4 (15.3, 40.3) 5.7 (1.2, 15.7) 0 (0.0, 6.6) Number of responders 14 3 0 Median DOR, months (range) 4.4 (1.9+, 6.0+) NR (1.8+, 3.8+) -- DCR, % (95% CI) 71.7 (57.7, 83.2) 67.9 (53.7, 80.1) 46.3 (32.6, 60.4) CI, confidence interval; DCR, disease control rate; DOR, duration of response; NR, not reached; ORR, objective response rate Conclusions In the first phase 3 study for a KRASG12C-inhibitor plus an anti-EGFR antibody in chemorefractory mCRC, the primary endpoint was met..."

Late-breaking abstract • Metastases • P3 data • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • KRAS

Efficacy of panitumumab in patients with left-sided disease, MSS/MSI-L, and RAS/BRAF WT: A biomarker study of the phase III PARADIGM trial. (ASCO 2023) - P3 | "Background: The PARADIGM trial (NCT02394795) showed longer median overall survival (OS) with first-line mFOLFOX6 plus panitumumab (PAN) vs bevacizumab (BEV) in patients (pts) with RAS wild type (WT) and left-sided metastatic colorectal cancer (mCRC; 37.9 vs 34.3 months, respectively; hazard ratio [HR], 0.82; P=0.031) and similar OS in right-sided pts (HR 1.09; Yoshino T, et al... These results support PAN + mFOLFOX6 as a first-line therapy for left-sided pts with MSS/MSI-L and RAS/BRAF WT. Clinical trial information: NCT02394795. >"

Biomarker • Clinical • P3 data • Colorectal Cancer • Gastrointestinal Cancer • Microsatellite Instability • Oncology • Solid Tumor • BRAF • KRAS • MSI • NRAS

Impact of age and gender on the efficacy and safety of panitumumab plus fluorouracil and folinic acid versus fluorouracil and folinic acid alone as maintenance therapy in RAS WT metastatic colorectal cancer (mCRC): Subgroup analysis of the PANAMA-study (AIO-KRK-0212). (ASCO 2022) - P2 | " PANAMA investigated the efficacy of panitumumab (Pmab) plus fluorouracil and folinic acid (FU/FA) versus FU/FA alone after first-line induction therapy with six cycles of FU/FA and oxaliplatin plus Pmab in patients with RAS wild-type metastatic colorectal cancer. In the Panama trial, addition of Pmab to maintenance treatment with FU/FA improved outcome in RAS wild-type mCRC. This effect is irrespective of age and is pronounced in male patients. Our results support the relevance of gender in mCRC."

Clinical • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

Targeting the EGFR pathway in chemotherapy-resistant triple-negative breast cancer - a phase II study. (PubMed, Cancer Res Commun) - P2 | "This study met its primary endpoint (pCR/RCB-I=30.2% vs. 5% in historical controls), suggesting that panitumumab should be evaluated as a component of neoadjuvant therapy in patients with chemotherapy-resistant TNBC in a larger, randomized clinical trial."

Clinical • Journal • P2 data • Breast Cancer • Hematological Disorders • Neutropenia • Oncology • Solid Tumor • Triple Negative Breast Cancer

Targeting glutamine metabolism and EGFR in RAS wildtype colorectal cancer (ESMO-GI 2023) - P1/2 | "We would also like to acknowledge support from Calithera Biosciences who supplied CB-839 for the study.Background: Alterations in glutamine metabolism have been proposed to play critical roles in cancer cell growth and survival. Panitumumab and CB-389 was very tolerable with some efficacy in heavily pre-treated patients. Early analysis of PET imaging data suggests a potential relationship between 18F-FSPG uptake and response, but additional studies are needed. It is anticipated that RNA-seq will identify genes that are related to glutamine avidity and represent a key determinate of response to inhibitors of glutamine metabolism."

Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • EGFR • RAS

Modified FOLFOXIRI plus panitumumab (mFOLFOXIRI/PAN) versus mFOLFOX6/PAN as initial treatment of unresectable RAS/BRAF wild-type metastatic colorectal cancer (mCRC) patients: results of the phase III randomized TRIPLETE study by GONO (ESMO-GI 2022) - P3 | "Background The association of a chemotherapy doublet (FOLFOX/FOLFIRI) with an anti-EGFR monoclonal antibody (cetuximab or panitumumab) is an upfront option for the treatment of RAS and BRAF wt mCRC patients...Methods TRIPLETE is a prospective, open label, phase III trial in which previously untreated patients with unresectable RAS and BRAF wt mCRC were randomized to receive mFOLFOX6/pan (arm A) or mFOLFOXIRI (irinotecan 150 mg/sqm, oxaliplatin 85 mg/sqm, L-leucovorin 200 mg/sqm, 5-fluoruracil 2400 mg/sqm 48 h infusion)/pan (arm B) up to 12 cycles, followed by 5FU/LV/pan until disease progression...Clinical trial info: NCT03231722. Conclusions The intensification of the upfront chemotherapy backbone in combination with panitumumab in molecularly selected and mostly (88%) left-sided mCRC patients does not provide any benefit in terms of treatment activity at the price of a non-negligible increase in gastrointestinal toxicity."

Clinical • P3 data • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • BRAF • RAS

Upfront modified FOLFOXIRI plus panitumumab (pan) versus FOLFOX/pan for unresectable RAS and BRAF wild-type (wt) metastatic colorectal cancer (mCRC) patients: Overall survival (OS) results from the phase III TRIPLETE study by GONO. (ASCO 2025) - P3 | "Upfront modified FOLFOXIRI/pan provides a statistically significant and clinically meaningful survival advantage compared to standard FOLFOX/pan in pts with RAS/BRAF wt mCRC, with a 7.8 mos difference in median values, though in the absence of any significant difference in treatment activity and PFS."

Clinical • Metastases • P3 data • Colorectal Cancer • Oncology • Solid Tumor • BRAF • RAS

Panitumumab retreatment followed by regorafenib versus the reverse sequence in chemorefractory metastatic colorectal cancer patients with RAS and BRAF wild-type circulating tumor DNA (ctDNA): Results of the phase II randomized PARERE trial by GONO. (ASCO 2025) - P2 | "PARERE is the largest randomized trial demonstrating an ORR and PFS advantage in favor of liquid biopsy-guided anti-EGFR re-tx, compared to regorafenib, in the late-line setting of RAS/BRAF wt mCRC. OR, Odds Ratio; CI, confidence interval; NA, not assessable; *Cox proportional hazards model; **stratified log-rank test according to ECOG PS; areference; bpts actually treated with rego and pani (A/B, N = 68/69)."

Circulating tumor DNA • Clinical • Late-breaking abstract • Metastases • P2 data • Colorectal Cancer • Oncology • Solid Tumor • BRAF • RAS

Acquired gene alteration patterns and post-progression survival: PARADIGM study analysis. (ASCO 2024) - P, P3 | "Background: In the phase 3 PARADIGM trial (NCT02394795), adding panitumumab (PAN) to FOLFOX6 improved overall survival (OS) compared with bevacizumab (BEV) in patients (pts) with RASWT mCRC. Distinctive patterns of acquired gene alterations were observed in PAN- and BEV-treated pts with PD. Co-occurrence of gene alterations, particularly in the RTK/RAS pathway, was more prevalent with PAN than BEV."

Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

The Role of Monoclonal Antibody Targeted Therapy (Panitumumab) in the Treatment of Metastatic Colorectal Cancer-A Narrative Review of Current Evidence and Emerging Therapeutic Strategies. (PubMed, Int J Mol Sci) - "The aim of this review is to summarize the role and potential of targeted therapies for colorectal cancer with monoclonal antibodies such as panitumumab or cetuximab, to provide current evidence on the position of panitumumab in the treatment of mCRC, and to discuss biomarkers and qualification strategies for targeted therapy, including the role of ctDNA in disease monitoring and rechallenge. Combining panitumumab with immune checkpoint inhibitors warrants further investigation, particularly in patients with MSS/pMMR mCRC. The observed activity of panitumumab in combination with nivolumab and ipilimumab provides a rationale for further clinical evaluation and monitoring."

Biomarker • IO biomarker • Journal • Review • Colorectal Cancer • Oncology • Solid Tumor • BRAF • HER-2 • KRAS